Estrogen Exhibits a Biphasic Effect on Prostate Tumor Growth through the Estrogen Receptor β-KLF5 Pathway by Nakajima Yuka et al.
Estrogen Exhibits a Biphasic Effect on
Prostate Tumor Growth through the Estrogen
Receptor β-KLF5 Pathway
著者 Nakajima Yuka, Osakabe Asami, Waku Tsuyoshi,
Suzuki Takashi, Akaogi Kensuke, Fujimura
Tetsuya, Homma Yukio, Inoue Satoshi,
Yanagisawa Junn
journal or
publication title
Molecular and cellular biology 
volume 36
number 1
page range 144-156
year 2016-01
権利 (C) 2015, American Society for Microbiology
URL http://hdl.handle.net/2241/00134889
doi: 10.1128/MCB.00625-15
1 
Estrogen exhibits a biphasic effect on prostate tumor growth through the ERβ-KLF5 1 
pathway 2 
3 
 4 
Yuka Nakajimaa,b#, Asami Osakabeb, Tsuyoshi Wakuc, Takashi Suzukid, Kensuke 5 
Akaogib, Tetsuya Fujimurae, Yukio Hommae, Satoshi Inouef,g,h, Junn Yanagisawaa,b  6 
 7 
Life Science Center of Tsukuba Advanced Research Alliance (Life Sci. Cent. of TARA)8 
a, Graduate School of Life and Environmental Sciencesb, University of Tsukuba, 9 
Tsukuba, Ibaraki, Japan; Graduate School of Pharmaceutical Sciences, University of 10 
Tokyo, Bunkyo-ku, Tokyo, Japanc; Department of Pathology and Histotechnology, 11 
Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japand; Departments 12 
of Urologye, Geriatric Medicinef, and Anti-Aging Medicineg, Graduate School of 13 
Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan; Division of Gene Regulation 14 
and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical 15 
University, Saitama, Japanh 16 
 17 
Running title: Biphasic effect of E2 on prostate tumor growth  18 
#Address correspondence to Yuka Nakajima, nakajima@tara.tsukuba.ac.jp 19 
 20 
Word count for the Materials and Methods: 1,383 words 21 
Combined word count for the Introduction, Results, and Discussion: 3,456 words 22 
23 
2 
 
Estrogens are effective in the treatment of prostate cancer; however, the effects of 24 
estrogens on prostate cancer are enigmatic.  In this study, we demonstrated that 25 
estrogen (17β-estradiol, E2) has biphasic effects on prostate tumor growth.  A lower 26 
dose of E2 increased tumor growth in mouse xenograft models using DU145 and PC-3 27 
human prostate cancer cells, whereas a higher dose significantly decreased tumor 28 
growth.  We found that anchorage-independent apoptosis in these cells was inhibited 29 
by E2 treatment.  Similarly, in vivo angiogenesis was suppressed by E2.  Interestingly, 30 
these effects of E2 were abolished by knockdown of either estrogen receptor β (ERβ) or 31 
Krüppel-like zinc-finger transcription factor 5 (KLF5).   Ιn addition, E2 suppressed 32 
KLF5-mediated transcription through ERβ, which inhibits pro-apoptotic FOXO1 and 33 
pro-angiogenic PDGFA expression.  Furthermore, we revealed that a non-agonistic ER 34 
ligand GS-1405 inhibited FOXO1 and PDGFA expression through ERβ and KLF5 35 
pathway, and regulated prostate tumor growth without ERβ transactivation.  Therefore, 36 
these results suggest that E2 biphasically modulates prostate tumor formation by 37 
regulating KLF5-dependent transcription through ERβ and provide a new strategy for 38 
designing ER modulators, which will be able to regulate prostate cancer progression 39 
with minimal adverse effects due to ER transactivation.40 
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INTRODUCTION 41 
Prostate cancer is the most frequently diagnosed cancer and the second leading cause of 42 
cancer death in the United States and other industrialized countries (1).  Prostate 43 
cancer progression is initially driven by androgens through androgen receptor (AR).  44 
Thus, androgen ablation therapy is the primary treatment approach for prostate cancer 45 
(2, 3).  However, almost all patients eventually develop resistance to anti-androgen 46 
therapy, which is extremely hard to cure (4).  Therefore, new molecular targets for 47 
devising novel therapies are required. 48 
Estrogens are known to play a role in the development of the male reproductive 49 
system and prostate cancer (5, 6).  The administration of estrogens has previously been 50 
extensively used in prostate cancer treatment.  Early research demonstrated that 51 
estrogens exert an indirect anti-androgen action mediated through feedback inhibition of 52 
luteinizing hormone-releasing hormone and pituitary luteinizing hormone release, 53 
thereby decreasing testicular androgen levels and release (7).  On the contrary, it is 54 
currently considered that estrogens modulate prostate cancer through non-androgenic 55 
pathways (7, 8).  In fact, estrogen (17β-estradiol, E2) inhibits the development of 56 
androgen-insensitive prostate cancer xenografts in mice (9, 10).  Moreover, clinical 57 
studies indicated that estrogenic therapies are useful for advanced and 58 
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androgen-insensitive prostate cancer (11, 12).  Despite these beneficial effects, E2 has 59 
also been revealed to be a risk factor of prostate carcinogenesis.  For example, several 60 
animal studies suggested that E2 could enhance prostate cancer growth (13, 14).  In 61 
addition, a recent clinicopathological study indicated that circulating E2 levels were 62 
significantly elevated in patients with prostate cancer compared with those in normal 63 
age-matched patients (15).  Thus, the molecular mechanisms underlying the 64 
contradictory effects of E2 on prostate cancer development are not well understood. 65 
E2 acts as a physiological ligand for two nuclear receptor isoforms, i.e., estrogen 66 
receptor (ER) α and ERβ (16, 17).  Synthetic compounds also regulate gene expression 67 
in prostate cancer cells through ERβ, which is the predominant ER subtype in those 68 
cells (18–20).  Being dependent on agonistic ligands such as E2, ER directly binds to 69 
estrogen response elements (EREs) within genomic DNA to induce gene expression 70 
(classical pathway) (21).  On the contrary, recent studies revealed that ERs can also 71 
regulate gene expression by interacting with other DNA-binding transcription factors, 72 
such as c-Fos/c-Jun, Sp1, and NF-κB, but not by binding directly to DNA (non-classical 73 
pathway) (22, 23).  Recent reports suggested that ER ligands regulate gene expression 74 
through ERβ-dependent non-classical pathways in prostate tissues and cancer cells 75 
(23–25).  We previously reported that prostate tumor growth is regulated through the 76 
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ERβ-dependent non-classical pathway with Krüppel-like zinc finger transcription factor 77 
5 (KLF5) (25).  KLF5 (also known as BTEB2 or IKLF) is a transcription factor that 78 
possesses both tumor-suppressing and tumor-promoting activities (26–28).  Analysis 79 
of the associated pathway revealed that in the absence of E2, ERβ induces the 80 
KLF5-mediated expression of FOXO1 and increases anoikis, thereby suppressing 81 
prostate tumor growth in mouse xenograft models.  Conversely, E2 suppresses KLF5 82 
transactivation through ERβ, which enhances tumor growth.  However, it is unclear 83 
whether and the mechanism by which E2 regulates prostate cancer progression through 84 
ERβ and KLF5. 85 
In this study, we demonstrated the mechanism underlying the modulation of 86 
prostate tumor formation by E2.  We revealed that E2 biphasically modulates prostate 87 
tumor growth in mouse xenograft models.  Our results using the non-agonistic ER 88 
ligand GS-1405 further indicated that the effect of E2 are exerted via the comprehensive 89 
regulation of FOXO1-mediated anoikis and PDGFA-mediated angiogenesis through the 90 
ERβ–KLF5 pathway.  These findings may lead to the development of new therapeutic 91 
strategies for designing next-generation ER modulators. 92 
 93 
 94 
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MATERIALS AND METHODS 95 
Cell culture and ligand treatment.  Human prostate cancer DU145 and PC-3 and 96 
human embryonic kidney HEK293 cells were obtained from the Cell Resource Center 97 
for Biomedical Research, Institute of Development, Aging and Cancer (Tohoku 98 
University, Miyagi, Japan).  Human prostate cancer LNCaP cells were obtained from 99 
American Type Culture Collection.  DU145, PC-3, and LNCaP cells were maintained 100 
in RPMI 1640 (Nacalai Tesque) and HEK293 cells were maintained in DMEM 101 
(Sigma-Aldrich).  All media were supplemented with 10% fetal bovine serum (FBS) 102 
and penicillin-streptomycin (Nacalai Tesque).  The medium was exchanged to phenol 103 
red-free medium containing 10% charcoal-stripped FBS and cells were cultured for 48 h 104 
before treatment with ligands.  17β-estradiol (E2), Fulvestrant (ICI 182,780, ICI), 105 
4-hydroxytamoxifen (OH-Tam), raloxifene (Ral) were purchased from Sigma-Aldrich.  106 
4-(6-methyl-1,3-benzothiazol-2-yl)phenol (GS-1405, GS; code LTBB000265) was 107 
purchased from Labtest. 108 
Tumor xenograft models.  All animal experiments were performed in 109 
accordance with the guidelines for the care and use of laboratory animals at University 110 
of Tsukuba.  Methods for keeping mice and tumor xenograft models have been 111 
described previously (25).  Each 5–6-week-old BALB/cA-nu castrated male mouse 112 
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was injected subcutaneously with 100 µl of cell suspension (6–8 × 106 cells) in both 113 
flanks.  Mice were subcutaneously implanted with 17β-estradiol (E2) pellets 114 
(Innovative Research of America) 0.18 mg (E2+) or 3.4 mg (E2++) 60 days release 115 
generating serum E2 concentration from 50 to 180 pg/ml or 550 to 1900 pg/ml, which 116 
were measured using Estradiol EIA kit (Cayman).  GS was subcutaneously injected in 117 
the scruff of the neck.  Tumor growth was monitored by measuring the tumor size 118 
using calipers; tumor volume was determined using the formula V = 1/2 × larger 119 
diameter × (smaller diameter)2.  Twenty-five to thirty-five days after implantation, 120 
tumors were excised, weighed, and fixed or stored in liquid nitrogen for later analysis. 121 
Expression plasmids and antibodies.  The pCMV5-FLAG-ERβ (WT) plasmid 122 
has been previously described (25).  To generate an expression plasmid for ERβ 123 
(E305A), site-directed mutagenesis of the ERβ sequence in pCMV5-FLAG-ERβ (WT) 124 
was performed by polymerase chain reaction (PCR) using the primers 125 
5′-gttggccgacaaggcgttggtacacatg-3′ and 5′-catgtgtaccaacgccttgtcggccaac-3′.  cDNAs 126 
encoding full-length PDGFA were amplified by PCR and subcloned into the pcDNA3 127 
plasmid (Invitrogen) containing sequences encoding a 6× myc sequence.  Mouse 128 
anti-PDGFA (E-10; Santa Cruz) and anti-β-actin (A5316; Sigma-Aldrich) monoclonal 129 
antibodies and rabbit anti-ERβ (CT; Millipore) and anti-CD31 (PECAM-1) (sc-1506; 130 
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Santa Cruz) polyclonal antibodies were used according to the manufacturer’s 131 
instructions.  The rabbit polyclonal antibodies against KLF5 and ERβ were previously 132 
generated (25). 133 
RNA interference.  Methods for stable RNA interference and siRNA 134 
transfection were followed those described by Nakajima et al (25).  To generate the 135 
shRNA retroviral supernatant, GP2-293 cells (Clontech) were cotransfected with the 136 
pVSV-G vector (Clontech) encoding envelope protein and pRETRO-SUPER 137 
(OligoEngine) vector containing the ERβ, KLF5, or luciferase (control) target sequence 138 
(25).  DU145 or PC-3 cells were incubated with the retroviral supernatant in the 139 
presence of 8 µg/ml polybrene.  The infected cells were selected with 1 µg/ml 140 
puromycin. 141 
Quantitative real-time (qRT)-PCR assay.  The qRT-PCR assay was 142 
performed as described previously (25), with minor modifications.  Cells were 143 
homogenized in 1 ml of Sepasol-RNA I Super G and total RNA was extracted, 144 
according to the manufacturer’s instructions (Nacalai Tesque).  cDNA was synthesized 145 
from total RNA using RevatraAce reverse transcriptase (Toyobo) and oligo dT primer.  146 
Real-time PCRs were performed to amplify fragments representing the indicated 147 
mRNAs using the Thermal Cycler Dice™ TP800 (Takara) and SYBR Premix Ex Taq II 148 
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(Takara).  mRNA levels were normalized to those of GAPDH.  The primer sequences 149 
were as follows: FOXO1 forward primer, 5′-tcatgtcaacctatggcag-3′; FOXO1 reverse 150 
primer, 5′-catggtgcttaccgtgtg-3′; PDGFA forward primer, 5′-tccacgccactaagcatgtg-3′; 151 
PDGFA reverse primer, 5′-cgtaaatgaccgtcctggtctt-3′; KLF5 forward primer, 152 
5′-atcgagatgttcgctcgtgc-3′; KLF5 reverse primer, 5′-tttaaaggcagacactgagtcag-3′; 153 
GAPDH forward primer, 5′-atcgtccaccgcaaatgcttcta -3′; and GAPDH reverse primer, 154 
5′-agccatgccaatctcatcttgtt -3′. 155 
TUNEL assay under detached conditions using poly-(2-hydroxyethyl 156 
methacrylate) (poly-HEMA) plats and using xenograft tissues.  One gram of 157 
poly-HEMA (Sigma-Aldrich) was dissolved in 25 ml of 99.5% ethanol and mixed 158 
overnight at 37°C (25).  The poly-HEMA stock solution was added to each well of 159 
12-well plates and the plates were left to dry for a few hours.  After drying, the plates 160 
were washed with PBS.  Cells were plated in the poly-HEMA–coated 12-well plates at 161 
a density of 60,000 (PC-3) or 200,000 cells (DU145)/well and incubated for 24 h.  162 
Apoptosis of the cells and xenograft tissues was analyzed by Dead End™ Fluorometric 163 
TUNEL System (Promega) and the kit was used according to the manufacturer’s 164 
instructions. 165 
Soft agar colony formation assay.  The procedure for colony formation assay 166 
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was performed as previously described (25).  In total, 22,000 cells were suspended in 167 
DMEM containing 0.35% agar (Sigma-Aldrich) and layered on top of 1 ml of DMEM 168 
solidified with 0.6% agar in each well of a six-well plate.  After growing at 37°C for 4 169 
weeks, colonies with a diameter >100 µm were observed and counted using Biozero 170 
(Keyence). 171 
Immunohistochemical analysis.  Immunohistochemistry for KLF5 was 172 
performed as previously described (25) with the following modification for CD31 and 173 
PDGFA staining.  Before incubation with anti-CD31 or anti-PDGFA antibodies, 174 
antigen retrieval was performed by microwave heating in EDTA buffer (1 mM, pH 8.0) 175 
or acid buffer (2 mM citric acid and 9 mM trisodium citrate dehydrate, pH 6.0), 176 
respectively.  The antigen antibody was visualized using 3,3′-diaminobenzide. 177 
Matrigel plug angiogenesis assay.  Matrigel angiogenesis experiments were 178 
performed for 7 days in 5–6-week-old castrated BALB/cA-nu mice under University of 179 
Tsukuba institutional approval.  Mice were injected with 200 µl of ice-cold Matrigel 180 
(BD Biosciences) mixed with 3 × 106 cells with or without 250 ng/ml recombinant 181 
PDGFA (PeproTech).  Seven days after the injection, Matrigel plugs were excised and 182 
the hemoglobin content in those plugs was determined using RIPA buffer (29). 183 
Immunoblotting.  Whole-cell lysates were extracted, and protein 184 
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concentrations were quantified using BCA protein assay reagent (Thermo Scientific).  185 
Cell extracts were fractionated by SDS-PAGE and transferred to a polyvinylidene 186 
difluoride membrane using a transfer apparatus, according to the manufacturer’s 187 
instructions (Bio-Rad).  Antibodies used were described above.  Secondary 188 
antibodies were used at a concentration of 1:2000. 189 
Patients and tissues.  Tumor specimens were obtained from 102 patients who 190 
provided informed consent and underwent radical prostatectomy between 1987 and 191 
2001 at Tokyo University Hospital.  The mean patient age was 66.0 years (range, 192 
52–75 years), the mean preoperative level of prostate-specific antigen was 16.7 ng/ml 193 
(3.2–136 ng/ml), and the mean follow-up period was 121 months (10–240 months).  194 
Thirty-seven patients were treated with surgery alone, whereas 65 patients received 195 
adjuvant anti-androgen therapy.  This study was approved by the ethics committee at 196 
Graduate School of Medicine, University of Tokyo (permission number 2283). 197 
Immunohistochemical assessment.  The immunoreactivity of KLF5 and 198 
PDGFA was evaluated in more than 1000 carcinoma cells for each case, and 199 
subsequently, the percentage of immunoreactivity, i.e., labeling index, was determined.  200 
Cases with cytoplasmic staining of PDGFA in more than 10% carcinoma cells were 201 
considered high immunoreactivity in this study. 202 
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Luciferase reporter assay.  For luciferase assays, cells were cotransfected with 203 
phRG(R2.2)-Basic (Promega) and FX-luc, or ERE-TATA-luc (25) with or without wild 204 
type or mutated ERβ expression plasmids.  Twenty-four hours after transfection, we 205 
replaced the culture medium with fresh medium containing ligands.  Twenty-four 206 
hours after incubation with the ligands, luciferase assays were performed on cell 207 
extracts using a Dual-luciferase Reporter Assay System (Promega), according to the 208 
manufacturer’s instructions. 209 
Structural modeling and description of the ERβ  ligand-binding domain 210 
(LBD) in complex with GS.  The AutoDock Vina program (30) and AutoDock tools 211 
(31) were used for the modeling of the ligand-receptor complex.  The protein structure 212 
of the hERβ LBD in complex with genistein was downloaded from the Protein 213 
Databank (PDB code: 1QKM) (32).  The exact conformation of hERβ LBD in 214 
complex with GS is unclear, in particular the H12 configuration.  Therefore, the 215 
H12-deleted hERβ LBD was used to the docking simulation to avoid the confusion.  216 
The model structure was described using UCSF Chimera software (33). 217 
Chromatin immunoprecipitation (ChIP).  This assay was conducted as 218 
described previously (25).  The purified DNA was analyzed to determine which DNA 219 
fragments were present in the precipitate by qRT-PCR, as described above.  The 220 
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primers for qRT-PCR were as follows: 5′-ccagcccggcgcccactggc-3′ and 221 
5′-cagcggctgctgcgactacc-3′ for the FOXO1 upstream region (25) and 222 
5′-gcactggagggtgggcaagc-3′ and 5′-gacccgcacctcggaagcgc-3′ for the PDGFA upstream 223 
region. 224 
Statistics.  Statistical significance was evaluated using one-way analysis of 225 
variance for multiple groups, followed by Tukey’s post hoc test to evaluate differences.  226 
Cancer-specific survival rates were evaluated based on Kaplan–Meier methods and 227 
statistical significance was determined using a log-rank test. 228 
 229 
 230 
RESULTS 231 
E2 exerts biphasic effects on prostate tumors growth in vivo.  Estrogens are known 232 
to regulate prostate cancer progression, although it remains controversial whether 233 
estrogens enhance or suppress prostate cancer growth through non-androgenic pathways 234 
(7, 8).  To clarify this point, we first evaluated the dose effect of E2 on prostate tumor 235 
formation by xenograft models using AR-negative DU145 or PC-3 prostate cancer cells, 236 
which express only ERβ or both ER subtypes (25, 34, 35).  Consistent with previously 237 
reported results (25), mice exposed to E2 pellets (E2+) developed larger tumors 238 
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compared with mice treated with placebo pellets (Fig. 1A).  Surprisingly, mice 239 
exposed to pellets containing a higher dose of E2 (E2++) had smaller tumors than those 240 
treated with placebo pellets (Fig. 1A).  Then, we investigated whether E2 biphasically 241 
regulated gene expression related to tumor growth.  To address this, we next 242 
investigated the expression levels of FOXO1, which acts as a tumor suppressor in 243 
prostate cancer by inducing apoptosis and which is inhibited by E2 (25, 36).  In cell 244 
lines and xenograft tumors, the expression levels of FOXO1 mRNA were reduced by 245 
treatment with both doses of E2 (Fig. 1B and C).  The percentages of TUNEL-positive 246 
cells were also reduced by E2 treatment in xenograft tumors (Fig. 1D) and in DU145 247 
and PC-3 cells which were cultured under anchorage-independent conditions (Fig. 1E).  248 
Moreover, an in vitro colony formation assay revealed that the anchorage-independent 249 
growth of DU145 or PC-3 cells was enhanced by E2 treatment (Fig. 1F).  These results 250 
indicate that E2 has a biphasic effect on prostate cancer cell growth in vivo but not in 251 
vitro.  252 
 253 
E2 suppresses in vivo angiogenesis and regulates tumor growth through ERβ and 254 
KLF5.  Angiogenesis plays an essential role during in vivo tumor growth (37, 38).  255 
Thus, we investigated whether angiogenesis is involved in the molecular mechanism 256 
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underlying the biphasic effect of E2 on prostate tumor growth.  We assessed vascular 257 
density in xenograft tumors via immunohistochemical staining for the endothelial cell 258 
marker CD31 and observed that the CD31-positive area was reduced in an E2 259 
concentration-dependent manner (Fig. 2A).  Then, we investigated the anti-angiogenic 260 
activity of E2 using an in vivo Matrigel plug angiogenesis assay.  DU145 or PC-3 cells 261 
were mixed with Matrigel and subcutaneously injected into mice, which were treated 262 
with or without E2.  Compared with Matrigel alone, Matrigel plugs containing DU145 263 
or PC-3 cells had a higher hemoglobin concentration (Fig. 2B).  When 264 
Matrigel-implanted mice were treated with E2, hemoglobin levels in 265 
Matrigel-containing prostate cancer cells were reduced.  These results indicate that E2 266 
inhibits in vivo angiogenesis induced by prostate cancer cells. 267 
We previously showed that E2 reduces KLF5 protein levels and inhibits 268 
KLF5-mediated anoikis in DU145 and PC-3 cells through ERβ (25).  We confirmed 269 
that KLF5 protein levels were reduced by E2 treatment in xenograft tumors (Fig. 2C).  270 
To further investigate whether ERβ and KLF5 are responsible for the E2-dependent 271 
modulation, we first performed a Matrigel plug assay using DU145 cells in which either 272 
ERβ or KLF5 was stably knocked down by shRNA (Fig. 2D).  Knockdown of ERβ or 273 
KLF5 decreased hemoglobin levels and abolished the effects of E2 on angiogenesis (Fig. 274 
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2E), indicating that both ERβ and KLF5 are necessary for the promotion and 275 
E2-mediated inhibition of in vivo angiogenesis.  Next, we investigated the possibility 276 
that the ERβ and KLF5 pathway contributes to the biphasic effect of E2 on prostate 277 
tumor growth using xenograft models of shERβ and shKLF5 cells.  The effect of E2 278 
on xenograft tumor growth was abolished by ERβ or KLF5 knockdown (Fig. 2F).  In 279 
addition, the reduction in FOXO1 mRNA levels by E2 treatment was not observed in 280 
shERβ or shKLF5 xenografts (Fig. 2G).  These data indicate that E2 modulates 281 
prostate tumor growth through the ERβ and KLF5 pathway. 282 
 283 
KLF5 knockdown inhibits both anoikis and angiogenesis, and exhibits biphasic 284 
effects on prostate tumor growth.  To assess the in vitro and in vivo effects of KLF5 285 
reduction on prostate tumor growth, we generated DU145 cell lines, shKLF5± and 286 
shKLF5−, in which KLF5 expression was reduced by approximately 50% and 90%, 287 
respectively (Fig. 3A and B).  The levels of FOXO1 mRNA and the number of 288 
anchorage-independent apoptotic cells were decreased in shKLF5± and shKLF5− cells 289 
(Fig. 3C and D).  Interestingly, the vascularization in Matrigel plugs containing those 290 
cells was decreased by both levels of KLF5 knockdown (Fig. 3E).  On the contrary, 291 
xenograft tumor growth was biphasically altered (Fig. 3F).  Similar results were 292 
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obtained from experiments using cell lines in which KLF5 expression was reduced by 293 
other shRNA target sequences (data not shown).  Taken together, our observations 294 
suggest that KLF5 exerts opposing functions on prostate tumor formation through 295 
inhibiting anoikis and angiogenesis. 296 
 297 
PDGFA is involved in the inhibitory effect of KLF5 on prostate tumor growth 298 
through angiogenesis.  To identify a KLF5 target gene that promotes angiogenesis 299 
induced by prostate cancer cells, we focused on PDGFA because this gene is regulated 300 
by KLF5, which plays a significant role in angiogenesis (39, 40).  We first revealed 301 
that PDGFA mRNA levels were decreased together with a reduction of KLF5 302 
expression in DU145 cells and tumors (Fig. 4A and B).  Next, we validated the effect 303 
of PDGFA on in vivo angiogenesis through KLF5.  To address this point, we injected 304 
Matrigel containing shKLF5− cells mixed with or without PDGFA protein into mice 305 
and observed that PDGFA recovered hemoglobin levels suppressed by KLF5 depletion 306 
(Fig. 4C).  Alternatively, we restored PDGFA levels in shCont. or shKLF5− cells by 307 
introducing myc-tagged PDGFA expression vectors (Fig. 4D) and injected these cells 308 
into mice.  PDGFA expression in shCont. cells (shCont. + PDGFA) did not markedly 309 
modulate xenograft tumor growth compared with the growth of control tumors (shCont. 310 
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+ EGFP) (Fig. 4E).  On the other hand, PDGFA expression in shKLF5− cells 311 
(shKLF5− + PDGFA) promoted tumor formation compared with those of shKLF5− + 312 
EGFP tumors.  In shKLF5− tumors, the ratio of CD31-positive region was recovered 313 
by PDGFA expression, but the ratio of TUNEL positive cells was not significantly 314 
changed (Fig. 4F and G).  Therefore, these results suggest that PDGFA is important 315 
for the inhibitory effect of KLF5 on prostate tumor growth through angiogenesis. 316 
Immunohistochemical staining of human prostate cancer tissues revealed that 317 
FOXO1 expression levels were positively correlated with KLF5 positivity and favorable 318 
cancer-specific survival in patients with prostate cancer (25).  We first 319 
immunohistochemically tested (Fig. 4H) the correlation between KLF5 320 
immunoreactivity and PDGFA expression levels in prostate cancer tissues.  KLF5 321 
immunoreactivity was higher in tumor samples expressing high levels of PDGFA than 322 
in samples expressing low levels of PDGFA (Fig. 4I; P = 0.0475), suggesting a positive 323 
correlation between the abundance of KLF5 and the expression levels of PDGFA.  324 
Next, we investigated the relationships between PDGFA immunoreactivity and the 325 
cancer-specific survival rate of patients with prostate cancer using the Kaplan–Meier 326 
method.  Patients with low PDGFA-expressing tumors had higher cancer-specific 327 
survival rates than patients with high PDGFA-expressing tumors (Fig. 4J; P = 0.02), 328 
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indicating that PDGFA expression is negatively correlated with the prognosis of 329 
patients with prostate cancer. 330 
 331 
E2 suppresses angiogenesis by inhibiting PDGFA expression through ERβ  and 332 
KLF5.  We next examined the inhibitory effect of E2 on angiogenesis that is mediated 333 
through PDGFA expression.  E2 treatment decreased PDGFA mRNA levels in DU145 334 
cells and its xenograft tumors (Fig. 5A and B).  Then, we investigated whether ERβ 335 
and KLF5 are also responsible for the E2-dependent suppression of PDGFA expression.  336 
The E2-dependent reduction of PDGFA mRNA levels was abrogated by knockdown of 337 
ERβ or KLF5 (Fig. 5C and D).  In the absent of E2, PDGFA mRNA levels were 338 
reduced by ERβ knockdown (Fig. 5C and D), supporting a role for unliganded ERβ as a 339 
coactivator of KLF5 (25).  To confirm the participation of PDGFA in angiogenesis 340 
inhibition by E2, we injected Matrigel containing DU145 cells mixed with or without 341 
PDGFA protein into mice and observed that E2-dependent reduction of hemoglobin 342 
levels was restored by PDGFA protein (Fig. 5E).  Thus, our results suggest that E2 343 
suppresses angiogenesis by inhibiting the ERβ- and KLF5-mediated expression of 344 
PDGFA. 345 
 346 
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The non-agonistic ER ligand GS inhibits the KLF5 pathway through ERβ .  347 
Previously, we identified GS as a non-agonistic ER ligand (Fig. 6A) (25).  We next 348 
investigated whether GS inhibits the ERβ and KLF5 pathway without enhancing the 349 
transactivation of ERβ. 350 
First, we compared the effects of GS and anti-estrogens on KLF5-mediated 351 
transcription using a luciferase assay with a FOXO1-promoter reporter construct 352 
containing KLF5-binding sites (FX-luc) (25).  As anti-estrogens, we used two 353 
selective estrogen receptor modulators, 4-hydroxytamoxifen (OH-Tam) and raloxifene 354 
(Ral), and one pure ER antagonist ICI 182,780 (ICI).  Consistent with the findings of 355 
our previous study (25), E2 inhibited KLF5-mediated transcription through ERβ, 356 
whereas ICI enhanced FOXO1 promoter activity in DU145 cells (Fig. 6B).  We also 357 
observed that GS inhibited the activity in a manner similar to that of E2.  On the other 358 
hand, OH-Tam and Ral did not affect the activity.  To validate whether GS functions 359 
through ERβ and KLF5, we additionally performed the FX-luc assay using shERβ and 360 
shKLF5 cells and showed that the inhibitory effect of GS was abolished by ERβ or 361 
KLF5 knockdown (Fig. 6C).  Then, we performed docking simulation between GS and 362 
the LBD of human ERβ (hERβ LBD).  In the model structure, GS formed a hydrogen 363 
bond network involving Glu305, Arg346, and a water molecule in the LBD (Fig. 6D).  364 
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Because these ligand–LBD interactions are important for the ERE-mediated 365 
transcription of ERβ induced by E2 (Fig. 6E) (41, 42), we introduced a point mutation 366 
in Glu305.  We confirmed that in contrast to E2, GS did not enhance ERE-mediated 367 
transcription (Fig. 6E).  The E305A mutation reduced the E2- and GS-induced 368 
transcriptional inhibition of FOXO1 promoter activity (Fig. 6F), confirming the 369 
inhibitory effects of these ligands on KLF5-mediated transcription through ERβ. 370 
Emerging studies have demonstrated that AR plays a critical role in prostate 371 
cancer development and progression, even after castration (43, 44).  Therefore, we 372 
investigated whether E2 and GS suppress KLF5-mediated transcription in the presence 373 
of AR using AR-positive LNCaP cells, which express KLF5 and ERβ (Fig. 6G).  In 374 
these cells, E2 and GS inhibited FOXO1 promoter activity, whereas the inhibitory 375 
effects were abolished by KLF5 or ERβ reduction (Fig. 6H).  These results suggest the 376 
possibility that E2 and GS may also inhibit the KLF5 pathway through ERβ in the 377 
presence of AR. 378 
We then investigated the effect of GS on the mRNA levels of KLF5 target genes.  379 
Similarly to E2, GS treatment decreased FOXO1 and PDGFA mRNA levels but not 380 
those of KLF5 in DU145 and PC-3 cells (Fig. 7A and B).  Furthermore, a ChIP 381 
experiment revealed that both ligands inhibited the binding of KLF5 to the FOXO1 or 382 
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PDGFA promoter regions containing functional or potential KLF5 response elements 383 
(25, 44) (Fig. 7C and D).  The inhibitory effects of E2 and GS were not observed in 384 
shERβ cells. 385 
Taken together, these results suggest that GS inhibits KLF5 recruitment to the 386 
target promoter through ERβ  for the suppression of KLF5-mediated transcription 387 
without enhancing ERβ transactivation. 388 
 389 
GS inhibits anoikis and angiogenesis, and regulates prostate tumor growth 390 
through ERβ .   Finally, we investigated the in vitro and in vivo effects of GS on 391 
prostate tumor growth.  To address this issue, we investigated whether GS affects 392 
anoikis and angiogenesis.  GS treatment decreased the number of apoptotic cells in 393 
poly-HEMA–coated plates (Fig. 8A).  In addition, GS inhibited angiogenesis in the 394 
Matrigel plugs containing prostate cancer cells (Fig. 8B).  Then, we used DU145 and 395 
PC-3 xenograft models to evaluate the effect of GS on prostate tumor growth.  396 
Compared with control mice treated with DMSO, mice treated with GS (GS+) 397 
developed larger tumors, whereas those injected with a higher dose of GS (GS++) had 398 
smaller tumors than control mice (Fig. 8C).  We confirmed that these effects of GS 399 
were abolished by ERβ knockdown (Fig. 8A–C).  These results suggest that the 400 
23 
 
non-agonistic ER ligand GS inhibits anoikis and angiogenesis through ERβ and 401 
modulates prostate tumor growth. 402 
 403 
 404 
DISCUSSION 405 
In this study, our results address the molecular basis of the paradoxical effects of E2 in 406 
prostate cancer.  Our previous results revealed that E2 treatment decreased 407 
KLF5-dependent FOXO1 transcription in prostate cancer cells though ERβ, thereby 408 
inhibiting apoptosis and increasing tumor weight in mouse xenograft models (25).  On 409 
the contrary, our present results showed that when mice were treated with higher doses 410 
of E2, prostate tumor growth was suppressed through ERβ and KLF5 in those models 411 
(Fig. 1A and 2F).  We also demonstrated that E2 inhibited PDGFA transcription and 412 
suppressed angiogenesis through ERβ and KLF5 (Fig. 2E, 5C, and D).  Moreover, 413 
PDGFA recovered angiogenesis inhibited by E2 (Fig. 5E).  Apoptosis serves as a 414 
natural barrier for cancer development (45).  Conversely, angiogenesis is indispensable 415 
for tumorigenesis (46).  Considering the previous reports together with our data, 416 
angiogenesis may be sufficient for tumor growth in mice treated with lower doses of E2, 417 
which enhances xenograft tumor growth through the inhibition of apoptosis.  On the 418 
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other hand, when both PDGFA and FOXO1 expressions were markedly suppressed by 419 
higher doses of E2, angiogenesis may be insufficient for prostate tumor growth, thereby 420 
suppressing tumor growth.  Therefore, our previous and present results suggest that E2 421 
biphasically regulates prostate tumor growth by suppressing FOXO1 and PDGFA 422 
expression levels through the ERβ-KLF5 pathway (Fig. 8D). 423 
In response to ligands, ERs initiate transcription by binding directly to EREs 424 
(classical pathway) or by interacting with other transcription factors (non-classical 425 
pathway) (22, 23).  Recently, we indicated that in the absent of a ligand, ERβ acts as a 426 
coactivator of KLF5 by recruiting CBP, thereby enhancing FOXO1 expression and 427 
anchorage-independent apoptosis (25).  In this study, we further found that in vivo 428 
angiogenesis was suppressed by ERβ depletion in the absent of ER ligands (Fig. 2E and 429 
8B).  ERβ depletion also reduced PDGFA mRNA levels in DU145 cells and xenograft 430 
tumors that were not treated with ER ligands (Fig. 5C and D).  Moreover, PDGFA was 431 
targeted by KLF5 (Fig. 4A, 4B, and 7D) and was involved in KLF5-mediated 432 
angiogenesis (Fig. 4C).  Taken together, these results suggest that unliganded ERβ 433 
regulates PDGFA expression through KLF5 transactivation and thereby mediates 434 
angiogenesis in vivo. 435 
In various cancers, including prostate cancer, KLF5 was inactivated by 436 
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chromosomal deletion, transcriptional silencing, and excessive protein degradation, 437 
thereby suggesting that KLF5 acts as a tumor suppressor (47–50).  On the contrary, in 438 
prostate cancer cells, KLF5 levels are most often decreased as a result of hemizygous 439 
deletion; KLF5 is hardly deleted homozygously (49).  Thus, these observations raise 440 
the possibility that KLF5 both possesses a tumor suppressive function and is also 441 
necessary for tumor formation.  In this study, we illustrated by knockdown 442 
experiments that an approximately 50% reduction of KLF5 expression in DU145 cells 443 
inhibited apoptosis under anchorage-independent conditions (Fig. 3D; shKLF5±).  The 444 
ratio of apoptosis was more strongly suppressed by a severe reduction of KLF5 445 
expression (Fig. 3D; shKLF5−).  Although these results suggest that shKLF5− cells 446 
possess the potential to form larger tumors than shKLF5± cells, we unexpectedly found 447 
that shKLF5− cells did not form tumors in mice (Fig. 3F).  In contrast, Matrigel plug 448 
assays indicated that KLF5 knockdown reduced angiogenesis (Fig. 3E).  Considering 449 
that angiogenesis plays an indispensable role in tumorigenesis (51, 52), our results 450 
suggest that prostate cancer cells, in which KLF5 has been homozygously deleted, may 451 
not be able to form tumors because of inhibited angiogenesis.   452 
KLF5 is involved in cancer development in a number of human tissues, although 453 
its function remains controversial (26, 27).  For instance, expression of KLF5 454 
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enhances cell proliferation in untransformed cells and transformed fibroblasts, whereas 455 
KLF5 suppresses cell growth in some cancer cells (28).  Recent reports disclosed that 456 
xenograft tumor growth was suppressed by the expression of wild-type KLF5 but 457 
enhanced by the expression of a deacetylated KLF5 mutant (K369R) in prostate cancer 458 
cells, suggesting that the roles of KLF5 are regulated by post-transcriptional 459 
modifications (53).  It is also known that KLF5 activity is regulated by steroid 460 
hormones in breast cancer cells (54, 55).  In fact, we found in this study that ER 461 
ligands inhibited KLF5-mediated transcription in prostate cancer cells (Fig. 6) and 462 
altered xenograft tumor growth (Fig. 1A and 8C).  Thus, specific roles of KLF5 in 463 
cancer development appear to be context-dependent, including post-transcriptional 464 
modifications and hormone levels.  Therefore, further studies are needed to address the 465 
mechanism underlying the modulation of prostate cancer tumorigenesis by KLF5. 466 
Estrogens, including the synthetic estrogen diethylstilbestrol, have previously 467 
been used in prostate cancer treatment; however, adverse effects limited their use (8, 56).  468 
These undesirable effects of estrogenic drugs are probably mediated in part by the 469 
transactivation of ERs (classical pathway) (57).  Our previous and present results 470 
showed that E2 enhanced the transcriptional activity of ERβ and suppressed that of 471 
KLF5, whereas the non-agonistic ER ligand GS inhibited KLF5-mediate transactivation 472 
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through ERβ (Fig. 6) (25).  We further revealed that high-dose GS inhibited 473 
angiogenesis and prostate tumor growth in mouse xenograft models through ERβ (Fig. 474 
8B and C).  These results suggest that selective inhibition of KLF5 activity via ERβ 475 
could be useful in prostate cancer therapies that minimize adverse effects caused by ER 476 
transactivation through the classical pathway.  Previous reports indicated that ERs bind 477 
to and modulate the transcriptional activity of several transcription factors, including 478 
Sp1, NF-κB, and AP1 (23, 58, 59).  According to our results, it is possible to develop 479 
compounds that regulate these transcription factors separately.  Therefore, our results 480 
provide a new strategy for designing next-generation ER modulators that can regulate 481 
non-classical pathways without affecting the classical pathway. 482 
 483 
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Figure Legends 665 
FIG 1 17β-estradiol (E2) has a biphasic effect on prostate tumor growth.  (A) E2 666 
biphasically regulates tumor formation in nude mice.  Mice were injected with DU145 667 
or PC-3 cells in both flanks and implanted with a control pellet (placebo) or a pellet 668 
containing 0.18 (E2+) or 3.4 mg (E2++) of E2 (released for 60 days).  Tumor growth 669 
curves are presented in left panels.  After 25 or 28 days, the xenografts were removed 670 
and weighed (right panel).  The middle panels show representative photographs of the 671 
tumors (scale bars, 1 cm).  (B, C) E2 treatment reduces FOXO1 mRNA levels in 672 
xenografts and prostate cancer cells.  (B) FOXO1 mRNA levels in the indicated 673 
xenograft tumors were determined by qRT-PCR.  (C) DU145 or PC-3 cells were 674 
cultured in the absence (DMSO) or presence of E2 (E2+, 10 nM; E2++, 1 µM).  675 
Twelve hours after treatment, FOXO1 mRNA levels were determined by qRT-PCR.   676 
(D, E) E2 inhibits apoptosis in xenografts and prostate cancer cells.  (D) DU145 and 677 
PC-3 xenograft tumors were examined in TUNEL assays.  (E) DU145 or PC-3 cells 678 
were seeded on poly-HEMA-coated plates in the presence of DMSO or E2 (E2+, 10 679 
nM; E2++, 1 µM).  After 24 h, the cells were examined in TUNEL assays.  (F) E2 680 
enhances the anchorage-independent growth of prostate cancer cells in soft agar.  681 
DU145 or PC-3 cells were plated on 0.35% soft agar plates in the presence of DMSO or 682 
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E2 (E2+, 10 nM; E2++, 1 µM).  Colonies with a diameter of more than 100 µm were 683 
counted.  Values are presented as mean ± SD. n = 4–6 for A, B, and D, n = 3 for C, E, 684 
and F. *, P < 0.05, **, P < 0.01. 685 
 686 
FIG 2 E2 modulates angiogenesis and tumor growth through ERβ  and KLF5.  687 
(A) E2 inhibits angiogenesis in DU145 and PC-3 xenograft tumors.  Paraffin sections 688 
of the indicated xenograft tumors were stained with antibodies for the blood vessel 689 
marker CD31, and the CD31 expression level was quantified by image analysis and 690 
expressed as a percentage of the control.  Scale bar, 100 µm.  (B, E) E2 inhibits 691 
angiogenesis induced by prostate cancer cells through ERβ and KLF5.  Nude mice 692 
were injected subcutaneously with Matrigel, with or without the indicated cells, and the 693 
vehicle (DMSO) or E2 (E2+, 21 µg/week; E2++, 210 µg/week).  Seven days after the 694 
injection, the Matrigel plugs were removed from the mice and homogenized.  The 695 
supernatant was analyzed for hemoglobin content.  The left panels show representative 696 
photographs of Matrigel plugs (scale bars, 0.5 cm).  (C) KLF5 protein levels are lower 697 
in tumors from E2-treated mice.  KLF5 protein levels in the indicated xenograft 698 
tumors were examined by immunoblotting.  (D) Endogenous ERβ or KLF5 expression 699 
was stably suppressed in DU145 cells following the introduction of ERβ shRNA 700 
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(shERβ) or KLF5 shRNA (shKLF5).  Those protein levels were determined by 701 
immunoblotting.  (F) E2 biphasically regulates tumor formation through ERβ and 702 
KLF5.  Mice were injected with the indicated knockdown DU145 cells in both flanks 703 
and implanted with a placebo, E2+, or E2++ pellet.  Tumor growth curves are 704 
presented in left panels.  After 35 days, the xenografts were removed and weighed 705 
(right panel).  (G) E2 reduces FOXO1 mRNA levels in xenografts through ERβ and 706 
KLF5.  FOXO1 mRNA levels in the indicated xenograft tumors were determined by 707 
qRT-PCR.  Values are presented as mean ± SD. n = 4–8 for A, B, and E to G. *, 708 
P < 0.05, **, P < 0.01; n.s., not significant. 709 
 710 
FIG 3 KLF5 knockdown suppresses anoikis and angiogenesis and exerts opposing 711 
functions on prostate tumor growth.  (A, B) KLF5 expression levels in shKLF5± 712 
and shKLF5− cells.  DU145 cells were transfected with luciferase shRNA (shCont) or 713 
KLF5 shRNA (shKLF5± or shKLF5−).  KLF5 mRNA (A) or protein levels (B) were 714 
determined by qRT-PCR or immunoblotting, respectively.  (C) KLF5 knockdown 715 
reduces FOXO1 mRNA levels in prostate cancer cells.  FOXO1 mRNA levels in the 716 
indicated cells were examined by qRT-PCR.  (D) KLF5 knockdown inhibits anoikis in 717 
prostate cancer cells.  The indicated cells were seeded on poly-HEMA-coated plates 718 
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and subjected to TUNEL assays.  (E) KLF5 knockdown inhibits angiogenesis induced 719 
by prostate cancer cells.  Hemoglobin content in plugs with or without the indicated 720 
cells was examined using a Matrigel plug assay (scale bars, 0.5 cm in the left panel).  721 
(F) KLF5 knockdown modulates prostate tumor growth in mice.  Nude mice were 722 
injected with the indicated cells in both flanks.  Tumor growth curves are presented in 723 
left panel.  After 28 days, the tumors were removed and weighed (right panel).  The 724 
middle panel shows representative photographs of the tumors (scale bar, 1 cm).  725 
Values are presented as mean ± SD. n = 3 for A, C, and D; n = 4–6 for E and F. *, 726 
P < 0.05, **, P < 0.01. 727 
 728 
FIG 4 PDGFA mediates the inhibitory effect of KLF5 on prostate tumor growth 729 
through angiogenesis.  (A, B) PDGFA mRNA levels are reduced by KLF5 730 
knockdown.  PDGFA mRNA levels in the indicated cells (A) or xenograft tumors (B) 731 
were determined by qRT-PCR.  (C) PDGFA recovers angiogenesis suppressed by 732 
KLF5 knockdown.  The indicated cells were mixed with Matrigel and the vehicle or 733 
PDGFA (500 ng/plug) and the mixture was subcutaneously injected into nude mice.  734 
The quantification of hemoglobin levels within Matrigel plugs is shown in the right 735 
panel.  The left panel shows representative photographs of Matrigel plugs (scale bar, 736 
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0.5 cm).  (D) PDGFA, KLF5, and FOXO1 expression levels in control or shKLF5− 737 
cells expressing EGFP or PDGFA.  DU145 cells were transfected with a combination 738 
of luciferase shRNA and EGFP expression plasmids (shCont + EGFP), luciferase 739 
shRNA and myc-tagged PDGFA expression plasmids (shCont. + PDGFA), KLF5 740 
shRNA and EGFP expression plasmids (shKLF5− + EGFP), or KLF5 shRNA and 741 
myc-tagged PDGFA expression plasmids (shKLF5− + PDGFA).  PDGFA, KLF5, and 742 
FOXO1 protein levels were determined by immunoblotting.  (E) PDGFA expression 743 
promotes tumor formation inhibited by KLF5 knockdown.  Nude mice were 744 
subcutaneously inoculated in both flanks with the indicated cells.  Tumor growth 745 
curves are presented in left panel.  After 28 days, the xenografts were removed and 746 
weighed (right panel).  The middle panel shows representative photographs of the 747 
tumors (scale bar, 1 cm).  (F, G) PDGFA expression recovers angiogenesis, but not 748 
changes apoptosis ratios in KLF5 knockdown xenograft tumors.  The indicated 749 
xenograft tumors were examined in immunostaining of CD31 (F) or TUNEL assays (G).  750 
Values are presented as mean ± SD. n = 3 for A and B; n = 4–9 for C and E to G. *, 751 
P < 0.05, **, P < 0.01; n.s., not significant.  (H) Representative prostate cancer tissues 752 
labeled with anti-KLF5 and anti-PDGFA antibodies (scale bars, 50 µm).  (I) 753 
Association between the KLF5 labeling index and PDGFA expression levels in prostate 754 
43 
 
cancer tissues.  Prostate cancer tissues were labeled with anti-KLF5 or anti-PDGFA 755 
antibodies.  “High” and “Low” indicate samples with either high (>10% positive 756 
carcinoma cells) or low (≤10% positive carcinoma cells) PDGFA immunoreactivity.  757 
(J) Clinical association of PDGFA with cancer-specific survival.  Cancer-specific 758 
survival rates were analyzed using the Kaplan–Meier method for high PDGFA- or low 759 
PDGFA-expressing samples. 760 
 761 
FIG 5 E2 inhibits angiogenesis through the suppression of PDGFA expression.  (A 762 
to D) E2 treatment reduces PDGFA mRNA levels through ERβ and KLF5.  DU145 763 
(A) or the indicated knockdown cells (C) were cultured in the absence (DMSO) or 764 
presence of E2 (E2+, 10 nM; E2++, 1 µM).  PDGFA mRNA levels in the indicated 765 
cells (A, C) or tumors (B, D) were determined by qRT-PCR.  (E) PDGFA counteracts 766 
the inhibition of angiogenesis induced by E2.  Nude mice were injected 767 
subcutaneously with Matrigel, with or without DU145 cells and proteins (PDGFA, 500 768 
ng/plug), and the vehicle or E2 (210 µg/week).  Quantification of hemoglobin levels 769 
within Matrigel plugs is shown in the right panel.  Representative photographs are 770 
displayed in the left panel (scale bar, 0.5 cm).  Values are presented as mean ± SD.  n 771 
= 3-6. *, P < 0.05, **, P < 0.01; n.s., not significant. 772 
44 
 
  773 
FIG 6 The non-agonistic ER ligand GS inhibits KLF5-mediated transcription 774 
through ERβ .  (A) Chemical structures of E2 and GS.  (B, C, and H) E2 and GS 775 
inhibit FOXO1 promoter activity through ERβ and KLF5.  A luciferase reporter 776 
plasmid containing the FOXO1 promoter (−83 to +56, FX-luc) was transfected into 777 
DU145 (B and C) or LNCaP (H) cells.  Cell extracts derived from cultures containing 778 
E2, GS, 4-hydroxytamoxifen (OH-Tam), raloxifene (Ral), or ICI 182,780 (ICI) (1 µM) 779 
were examined using luciferase assays.  (D) GS forms the hydrogen bond with the 780 
hERβ LBD in docking model.  GS is represented as a ball-and-stick model (cyan), 781 
whereas ligand-interacting residues are represented as sticks (light blue).  Hydrogen 782 
bonds between GS and the hERβ LBD are indicated as red lines.  The main chain of 783 
the hERβ LBD (PDB 1QKM) is represented with a cartoon model (transparent blue).  784 
(E) E2, but not GS, enhances ERE-mediated transcription.  ER-negative HEK293 cells 785 
were transfected with ERE-TATA-luc and the indicated ERβ expression plasmid.  786 
Transfected cells were then treated with E2 or GS (10 nM) for 24 h before the 787 
preparation of extracts.  Cell extracts derived from cultures were examined using 788 
luciferase assays.  (F) E305A mutation of ERβ abolishes the inhibition of FOXO1 789 
expression by GS.  FX-luc and the indicated ERβ expression plasmid were transfected 790 
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into HEK293 cells.  Cell extracts derived from cultures containing the indicated ER 791 
ligands (1 µM) were examined using luciferase assays.  (G) Endogenous KLF5 or ERβ 792 
expression was suppressed in LNCaP cells following the introduction of KLF5 siRNA 793 
(siKLF5) or ERβ siRNA (siERβ).  Those protein levels were determined by 794 
immunoblotting.  Values are presented as mean ± SD. n = 3-4. **, P < 0.01; n.s., not 795 
significant. 796 
 797 
FIG 7 E2 and GS suppress FOXO1 and PDGFA expression through inhibiting 798 
KLF5 interaction to those promoter regions.  (A) GS treatment reduces FOXO1 and 799 
PDGFA mRNA levels in prostate cancer cells.  DU145 or PC-3 cells were cultured in 800 
the absence (DMSO) or presence of GS (GS+, 10 nM; GS++, 1 µM), and FOXO1 or 801 
PDGFA mRNA levels were determined by qRT-PCR.  (B) E2 or GS treatment does 802 
not affect KLF5 mRNA levels.  DU145 or PC-3 cells were cultured in the absence 803 
(DMSO) or presence of E2 or GS (1 µM) and KLF5 mRNA levels were determined by 804 
qRT-PCR.  (C, D) E2 or GS treatment inhibits the binding of KLF5 to the FOXO1 (C) 805 
and PDGFA promoter regions (D) through ERβ.  Control (shCont.) and ERβ 806 
knockdown (shERβ) DU145 cells were cultured in the absence (DMSO) or presence of 807 
the indicated ER ligands (1 µM).  ChIP assays were performed using anti-KLF5 808 
46 
 
antibodies.  Immunoprecipitated DNA was assessed in qRT-PCR assays using primers 809 
specific for the FOXO1 or PDGFA promoter.  Samples were normalized to the input 810 
DNA.  Values are presented as mean ± SD. n = 3. *, P < 0.05; **, P < 0.01; n.s., not 811 
significant. 812 
 813 
FIG 8 GS regulates prostate tumor growth through the inhibition of anoikis and 814 
angiogenesis.  (A) GS suppresses anoikis in prostate cancer cells.  DU145 or PC-3 815 
cells were seeded onto poly-HEMA–coated plates in the presence of DMSO or GS 816 
(GS+, 10 nM; GS++, 1 µM).  After 24 h, the cells were examined by TUNEL assays.  817 
(B) GS inhibits in vivo angiogenesis through ERβ.  Hemoglobin content in plugs with 818 
the indicated cells treated with or without GS (GS+, 5 mg/week; GS++, 25 mg/week) 819 
was examined using a Matrigel plug assay (scale bars, 0.5 cm).  (C) GS modulates 820 
prostate tumor growth.  Nude mice were injected with the indicated cells followed by 821 
the vehicle (DMSO) or GS (GS+, 5 mg/week; GS++, 25 mg/week).  Tumor growth 822 
curves are presented in left panel.  After 28 days, the tumors were removed and 823 
weighed (right panels).  The middle panel shows representative photographs of the 824 
tumors (scale bar, 1 cm).  (D) A schematic model of the mechanism by which E2 or 825 
GS biphasically regulates prostate tumor growth.  Values are presented as mean ± SD. 826 
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n = 3 for A; n = 4–8 for B and C. **, P < 0.01; n.s., not significant. 827 
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